HUP0204216A2 - A new use of antibodies as vaccines - Google Patents

A new use of antibodies as vaccines

Info

Publication number
HUP0204216A2
HUP0204216A2 HU0204216A HUP0204216A HUP0204216A2 HU P0204216 A2 HUP0204216 A2 HU P0204216A2 HU 0204216 A HU0204216 A HU 0204216A HU P0204216 A HUP0204216 A HU P0204216A HU P0204216 A2 HUP0204216 A2 HU P0204216A2
Authority
HU
Hungary
Prior art keywords
antibodies
immunoaffinity purification
vaccines
associated antigens
new use
Prior art date
Application number
HU0204216A
Other languages
English (en)
Inventor
Helmut Eckert
Gottfried Himmler
Hans Loibner
Original Assignee
Igeneon Krebs Immuntherapie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Igeneon Krebs Immuntherapie filed Critical Igeneon Krebs Immuntherapie
Publication of HUP0204216A2 publication Critical patent/HUP0204216A2/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

A találmány tárgyát olyan antitestek alkalmazása képezi, amelyektumor-asszociált antigének elleni antitestekhez kötődnek, és aamelyeket antitesteket tartalmazó individuális testfolyadékokbólizolálnak specifikus ligandumokon végzett immunaffinitás tisztítással.Az említett antitesteket olyan készítmény előállítására használják,amely rákbetegségek elleni individuális, autológ, profilaktikus vagyterápiás vakcinálásához alkalmas. Az immunaffinitás tisztításhozhasznált ligandumok olyan antitestek vagy ezek származékai, amelyektumorasszociált antigének ellen irányulnak. A találmány ezenfelülolyan gyógyszerkészítményekre vonatkozik, amelyek immunaffinitás-tisztítással kapott antitesteket tartalmaznak, vagy az ezenantitestekkel in vitro pulzált dendritikus sejteket tartalmazzák. Ó
HU0204216A 1999-11-16 2000-11-15 A new use of antibodies as vaccines HUP0204216A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AT0192799A AT409086B (de) 1999-11-16 1999-11-16 Neue verwendung von antikörpern als impfstoffe
PCT/EP2000/011306 WO2001035989A2 (de) 1999-11-16 2000-11-15 Verwendung von anti-idiotypische antikörpern als impfstoffe gegenkrebs

Publications (1)

Publication Number Publication Date
HUP0204216A2 true HUP0204216A2 (en) 2003-04-28

Family

ID=3524036

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0204216A HUP0204216A2 (en) 1999-11-16 2000-11-15 A new use of antibodies as vaccines

Country Status (24)

Country Link
EP (1) EP1229936B1 (hu)
JP (1) JP2003514028A (hu)
KR (1) KR20020060968A (hu)
CN (1) CN1390138A (hu)
AT (1) AT409086B (hu)
AU (1) AU780853B2 (hu)
BR (1) BR0015597A (hu)
CA (1) CA2391927A1 (hu)
CZ (1) CZ20021707A3 (hu)
DE (1) DE50006526D1 (hu)
DK (1) DK1229936T3 (hu)
EE (1) EE200200252A (hu)
ES (1) ES2218272T3 (hu)
HU (1) HUP0204216A2 (hu)
IL (1) IL149614A0 (hu)
IS (1) IS6381A (hu)
MX (1) MXPA02004942A (hu)
NO (1) NO20022333L (hu)
NZ (1) NZ518669A (hu)
PL (1) PL356770A1 (hu)
PT (1) PT1229936E (hu)
SK (1) SK6542002A3 (hu)
TR (1) TR200401267T4 (hu)
WO (1) WO2001035989A2 (hu)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4017108A (en) * 1975-04-17 1977-04-12 Archibald Kenrick And Sons Limited Window stay
US6294171B2 (en) * 1999-09-14 2001-09-25 Milkhaus Laboratory, Inc. Methods for treating disease states comprising administration of low levels of antibodies
AT410172B (de) * 2000-03-21 2003-02-25 Igeneon Gmbh Verfahren zur herstellung einer vakzineformulierung
AT410637B (de) * 2001-06-01 2003-06-25 Igeneon Krebs Immuntherapie Verwendung von polyklonalen immunglobulinen
AT502293B1 (de) * 2002-05-15 2008-03-15 Igeneon Krebs Immuntherapie Immunogener, monoklonaler antikörper
AT500648B1 (de) * 2002-08-12 2010-03-15 Igeneon Krebs Immuntherapie Set zur behandlung von krebspatienten
KR100522526B1 (ko) * 2002-11-28 2005-10-19 주식회사 바이넥스 면역 치료용 수지상 세포의 제조방법
AT500650B1 (de) 2003-04-17 2009-11-15 Altropus Gmbh Immunogener rekombinanter antikörper
WO2007024825A2 (en) * 2005-08-26 2007-03-01 Genway Biotech, Inc. Immunoaffinity separation and analysis compositions and methods
EP2044949A1 (en) 2007-10-05 2009-04-08 Immutep Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
GB201322626D0 (en) 2013-12-19 2014-02-05 Immutep S A Combined preparations for the treatment of cancer
US20180008702A1 (en) * 2014-12-05 2018-01-11 Celltrion Inc. Adjuvant composition containing at least one influenza virus neutralizing and binding molecule and vaccine composition containing same
GB201500374D0 (en) 2015-01-09 2015-02-25 Immutep S A Combined preparations for the treatment of cancer

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1984002848A1 (en) * 1983-01-28 1984-08-02 Centocor Inc Anti-idiotypic antibodies to t cell antigen receptors
ES2015654A6 (es) * 1988-05-17 1990-09-01 Soldano Ferrone Un procedimiento para preparar anticuerpos anti-idiotipicos para antigeno asociado con melanoma, de alto peso molecular anti-humano.
US20030072751A1 (en) * 1990-03-14 2003-04-17 Heribert Bohlen Idiotypic vaccination against b cell lymphoma
IT1254315B (it) * 1992-03-27 1995-09-14 Mini Ricerca Scient Tecnolog Anticorpi monoclonali anti-idiotipici diretti contro anticorpi anti-tnf.
WO1994001133A1 (en) * 1992-07-08 1994-01-20 Schering Corporation Use of gm-csf as a vaccine adjuvant
CA2209172C (en) * 1994-12-28 2007-04-10 University Of Kentucky Murine monoclonal anti-idiotype antibody 3h1

Also Published As

Publication number Publication date
AT409086B (de) 2002-05-27
JP2003514028A (ja) 2003-04-15
PT1229936E (pt) 2004-09-30
EE200200252A (et) 2003-06-16
WO2001035989A2 (de) 2001-05-25
KR20020060968A (ko) 2002-07-19
NO20022333D0 (no) 2002-05-15
CN1390138A (zh) 2003-01-08
IL149614A0 (en) 2002-11-10
NO20022333L (no) 2002-06-03
IS6381A (is) 2002-05-14
AU780853B2 (en) 2005-04-21
DE50006526D1 (de) 2004-06-24
EP1229936A2 (de) 2002-08-14
AU2357201A (en) 2001-05-30
ATA192799A (de) 2001-10-15
NZ518669A (en) 2003-08-29
TR200401267T4 (tr) 2004-07-21
ES2218272T3 (es) 2004-11-16
EP1229936B1 (de) 2004-05-19
BR0015597A (pt) 2002-07-23
WO2001035989A3 (de) 2001-10-04
CZ20021707A3 (cs) 2002-10-16
MXPA02004942A (es) 2003-10-14
SK6542002A3 (en) 2002-11-06
CA2391927A1 (en) 2001-05-25
DK1229936T3 (da) 2004-08-30
PL356770A1 (en) 2004-07-12

Similar Documents

Publication Publication Date Title
HUP0103598A2 (hu) Készítmények és eljárások WT1-specifikus immunterápiás alkalmazásra
HUP0302532A2 (hu) Petefészekrák terápiájában és diagnosztizálásában alkalmazható készítmények és eljárások
TR200103018T2 (tr) İmmünostimülatör oligonükleotid ve saponin içeren katkı bileşikleri.
HUP0401753A2 (hu) Antigénprezentáló sejtek, készítésükre szolgáló eljárások és rákvakcinaként történő alkalmazásuk
HUP0204216A2 (en) A new use of antibodies as vaccines
HUP0402067A2 (hu) Oltóanyagok
ATE456378T1 (de) Behandlung und verhütung von neoplasmatischen und infektiösen erkrankungen mit hitzeschock / stress proteinen
ATE314095T1 (de) Virusähnliche partikel zur induktion von autoantikörpern
ES2158943T3 (es) Peptidos derivados del precursor del antigeno de rechazo tumoral mage-2 aislados, y usos de los mismos.
IL138424A (en) Covalently reactive antigen analogs and pharmaceutical compositions containing the same
HUP0303372A2 (hu) Vakcina
CY1105179T1 (el) Φαρμακα για την ανοσοθepαπεια κακοηθων ογκων
HUP0004780A2 (hu) Prosztaglandin agonisták felhasználása merevedési rendellenességek vagy impotencia kezelésében
TR200102034T2 (tr) Anti kanser aşılaması için antikorların kullanılması
DE50008756D1 (de) Peptid aus antigen muc-1 zur auslösung einer immunreaktion gegen tumorzellen
DE69530380D1 (de) Retropeptide, antikörper dagegen und deren verwendungen in der impfung und in vitro diagnostik
ATE514780T1 (de) Zusammensetzungen für die therapie und diagnose von brustkrebs und verwendung davon
HUP0302566A2 (hu) Készítmények és eljárások emlőrák gyógykezelésére és diagnosztizálására
JP2005524719A5 (hu)
SE0000597D0 (sv) Novel antibody
HUP0300923A2 (hu) RAF és RAS protein kinázt tartalmazó készítmények és alkalmazásuk angiogenezis módosítására
AR027738A1 (es) Composicion coadyuvante, composiciones de vacunas que incluyen dicha composicion coadyuvante; procedimiento de induccion de inmunorespuestas antigenicas enmamiferos y procedimiento de tratamiento donde se aplican dichas vacunas
HUP0003511A2 (hu) Hepatitisz-B-vírus polipeptidek
DK1444261T3 (da) Immunogene ALK (anaplastisk lymfomakinase) peptider
AU2002242725A1 (en) Mhc-i-restricted presentation of hiv-1 virion antigens without viral replication. application to the stimulation of ctl and vaccination in vivo; analysis of vaccinating composition in vitro

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees